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Abstract
Aquatic birds harbor diverse influenza A viruses and are a major viral reservoir in nature. The recent discovery of influenza
viruses of a new H17N10 subtype in Central American fruit bats suggests that other New World species may similarly carry
divergent influenza viruses. Using consensus degenerate RT-PCR, we identified a novel influenza A virus, designated as
H18N11, in a flat-faced fruit bat (Artibeus planirostris) from Peru. Serologic studies with the recombinant H18 protein
indicated that several Peruvian bat species were infected by this virus. Phylogenetic analyses demonstrate that, in some
gene segments, New World bats harbor more influenza virus genetic diversity than all other mammalian and avian species
combined, indicative of a long-standing host-virus association. Structural and functional analyses of the hemagglutinin and
neuraminidase indicate that sialic acid is not a ligand for virus attachment nor a substrate for release, suggesting a unique
mode of influenza A virus attachment and activation of membrane fusion for entry into host cells. Taken together, these
findings indicate that bats constitute a potentially important and likely ancient reservoir for a diverse pool of influenza
viruses.
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Introduction
Influenza viruses originating from animals caused the three
major influenza pandemics of the previous century. Swine were a
gateway for avian influenza virus genes to enter human
populations as reassortant viruses and also initiated the influenza
(H1N1) pandemic of 2009 [1]. The recent discovery of novel
influenza A viruses in Guatemalan yellow-shouldered fruit bats
identified another mammalian species that may serve as an
important source of influenza virus genetic diversity and support
reassortment with human influenza viruses [2]. Bats are a major
source of emerging infectious diseases, including coronaviruses,
filoviruses, henipaviruses, and lyssaviruses [3–5]. Their global
distribution, abundance, diversity (,1200 species) and high
population densities underscore the need to better understand
the ecology and properties of influenza viruses that infect this
mammalian order, as well as the potential of viral jumps
across species barriers to emerge in new hosts [5]. These
considerations prompted additional searches for species harboring
novel influenza A viruses within the Americas, and detailed
characterization of the virus-host interactions at the molecular and
atomic levels.
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Results
A novel influenza virus in Peruvian bats
We sampled 114 Peruvian bats captured during 2010 in
Truenococha and Santa Marta, two communities located in the
Loreto Department, Peru, a remote and sparsely populated area in
Amazonia (Table 1 and Fig. S1). The sampled bats comprised 18
species, although 12 species were represented by four or fewer
animals (Table 1). Initial screening of the available 110 rectal
swabs with a pan Flu RT-PCR assay identified a flat-faced fruit
bat (ID PEBT033) (Artibeus planirostris) from Truenococha as
positive for influenza virus. Of the other available specimens,
i.e. liver, intestine and spleen tissues from bat PEBT033, the
intestine tissue specimen was strong positive whereas others were
negative. A BLAST search based on the 250 nt sequence of the
PB1 RT-PCR amplicon showed that the influenza gene in the
PEBT033 bat was most closely related (77% nt identity) to the
PB1 genes of recently described bat influenza viruses, e.g. A/
little yellow-shouldered bat/Guatemala/164/2009 (H17N10).
The RNA from bat PEBT033 rectal swab sample was analyzed
by Sanger and deep sequencing as described previously [2] to
generate a full-length genomic sequence (GenBank accession
numbers CY125942-CY125949), and this virus was designated A/
flat-faced bat/Peru/033/2010 (A/bat/Peru/10) (Table S1).
Evolution of bat influenza viruses
Phylogenetic analysis indicated that all genes of A/bat/Peru/10
were most closely related to those of bat influenza viruses from
Guatemala, although forming a distinct lineage (Fig. 1). With the
notable exception of the HA, the bat virus genes (i) fell as an
outgroup to all other known influenza A viruses, and (ii) in four
gene segments (PB2, PB1, PA and NA) harbored more genetic
diversity than those present in all non-bat (i.e. avian, mammalian)
groups combined [2]. Considering the limited geographic area and
bat species numbers sampled in the Americas, the remarkable
divergence between A/bat/Peru/10 and Guatemalan bat viruses
in these four gene segments suggests that New World bat species
may carry a diverse pool of influenza viruses. In contrast, the bat
HA gene sequences represented a distinct lineage within the
known diversity of this gene [2].
The differing phylogenetic position of the bat HA genes relative
to the other seven gene segments indicates that a reassortment
event took place after gene divergence into the bat and non-bat
lineages (Fig. 1). In contrast, the phylogeny of the NA gene
Table 1. Detection of influenza A virus and antibody in bats from Peru (2010).
Species Location (number captured) Pan Flu RT-PCR +, tested bats Seroprevalence +, tested sera
Artibeus lituratus Truenococha (3) 0, 3 3, 3
Artibeus obscurus Santa Marta (1); Truenococha(9) 0, 10 9, 10
Artibeus planirostris Santa Marta (1); Truenococha(14) 1, 15 13, 15
Carollia brevicauda Santa Marta (2) 0, 2 1, 2
Carollia castanea Santa Marta (2) 0, 2 0, 2
Carollia perspicillata Santa Marta (26); Truenococha(4) 0, 29 11, 29
Desmodus glaucus Truenococha(1) 0, 1 0, 1
Desmodus rotundus Santa Marta (12); Truenococha(6) 0, 18 7, 18
Diphylla ecaudata Santa Marta (1) 0, 1 0, 1
Glossophaga soricina Santa Marta (1); Truenococha(3) 0, 2 0, 2
Molossus molossus Santa Marta (10) 0, 10 3, 10
Myotis sp. Santa Marta (6) 0, 6 1, 6
Phyllostomus discolor Santa Marta (1); Truenococha(1) 0, 2 2, 2
Phyllostomus hastatus Truenococha (2) 0, 2 2, 2
Platyrrhinus recifinus Truenococha (1) 0, 1 1, 1
Rhinophylla pumilio Santa Marta (2) 0, 2 1, 2
Sturnira sp. Santa Marta (2) 0, 2 0, 2
Vampyressa bidens Truenococha (3) 0, 2 1, 2
doi:10.1371/journal.ppat.1003657.t001
Author Summary
Previous studies indicated that a novel influenza A virus
(H17N10) was circulating in fruit bats from Guatemala
(Central America). Herein, we investigated whether similar
viruses are present in bat species from South America.
Analysis of rectal swabs from bats sampled in the Amazon
rainforest region of Peru identified another new influenza
A virus from bats that is phylogenetically distinct from the
one identified in Guatemala. The genes that encode the
surface proteins of the new virus from the flat-faced fruit
bat were designated as new subtype H18N11. Serologic
testing of blood samples from several species of Peruvian
bats indicated a high prevalence of antibodies to the
surface proteins. Phylogenetic analyses demonstrate that
bat populations from Central and South America maintain
as much influenza virus genetic diversity in some gene
segments as all other mammalian and avian species
combined. The crystal structures of the hemagglutinin
and neuraminidase proteins indicate that sialic acid is not a
receptor for virus attachment nor a substrate for release,
suggesting a novel mechanism of influenza A virus
attachment and activation of membrane fusion for entry
into host cells. In summary, our findings indicate that bats
constitute a potentially important reservoir for influenza
viruses.
Bat Influenza Virus
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resembles that of ‘‘internal genes’’ (PB2, PB1, PA, NP, MP, NS)
rather than the HA, an intriguing finding given the functional
interdependence of these genes in non-bat influenza viruses (Fig. 1).
Overall, the magnitude of the evolutionary distance between
A/bat/Peru/10 and A/bat/Guatemala/164/09 in the HA and
NA genes, previously classified as subtype H17N10, would support
Figure 1. Evolution of influenza virus in New World bats. (a) Phylogenetic relationships of influenza A viruses sampled from bats (red
branches) and other animals (‘non-bat’, black branches) based on the amino acid sequences of each gene segment. (b) The maximum amino acid
distances are shown within and between the bat and non-bat sequences, and colored accordingly. These levels of diversity also effectively act as a
scale-bar for the trees shown above.
doi:10.1371/journal.ppat.1003657.g001
Bat Influenza Virus
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its designation as an H18N11 virus, comprising new HA and NA
subtypes [2]. In particular, these bat viruses are more diverse than
some recognized HA and NA subtypes (for example, H13 and
H16; N5 and N8; Fig. 1), which is clearly compatible with their
classification as distinct subtypes (also see below).
Genome and proteome of bat influenza viruses
Key structural features of the Peruvian bat influenza virus
genome, including RNA transcription and replication promoter
elements, open reading frames and mRNA splice signals, and
ribosomal frameshift element (PA gene), are nearly identical to the
recently described Guatemalan bat influenza genomes and likely
to serve equivalent functions [6,7]. Comparison of the genomes of
the two viruses shows nucleotide sequence identity of 48.7–62.3%
for genes encoding viral surface proteins and 76.2 to 81.6% for
those encoding internal proteins (Table S1).
The influenza HA and NA proteins are critical for interaction
with the host and determining the subtype of influenza type A
viruses. The mean pairwise amino acid sequence identity of the HA
of A/bat/Peru/10 with Group 1 HA subtypes is 49.1% (Table S2).
Despite such divergence, canonical sequence motifs conserved
across non-bat subtypes of HA, such as putative disulfides, the
receptor binding site (RBS), HA0 cleavage sites, coiled-coil heptad
repeats and the fusion peptide, are readily identified (Table S3). The
HA proteins from A/bat/Peru/10 and the recently identified H17
from Guatemalan bat share only 60.2% sequence identity (Table
S2). This divergence is greater than the pairwise differences (Table
S2) between 14 of the 136 possible pairwise comparisons between all
subtypes, again supporting the designation of the new HA as
representative of novel H18 subtype [8]. The NA-like (NAL) protein
of A/bat/Peru/10 has only 29.6% identity with all other NA
subtypes that correlates with poor residue conservation comprising
the canonical catalytic site [9] (Tables S4 and S5) and supports the
proposed designation of A/bat/Peru/10 NAL as subtype N11.
The amino-acid sequences of the internal genes of A/bat/Peru/
10 retain most of the known functional sequence motifs of other
influenza A viruses with few amino-acid substitutions compared to
the consensus amino acids at these sites in non-bat viruses
(Table 2). To evaluate transcription and replication functions of
the A/bat/Peru/10 polymerase complex proteins 4P (PB2, PB1,
PA, and NP), we used a minigenome reporter replicon system
coupled to transient expression by transfected DNA [10]. In this
assay, a mini-genome reporter plasmid, in which luciferase
expression is driven by non-coding regions (NCR) from bat
(Guat/164.NS-NCR) or human (WSN.NS-NCR) influenza virus,
showed high levels of viral transcription when co-transfected with
a complete polymerase complex 4P from bat viruses, as compared
to control with a plasmid set lacking the PB1 protein (Guat/164-
3P) (Fig. S2). The activity of A/bat/Peru/10 RNP complex (Peru/
033-4P) with the bat influenza minigenome was 5-fold lower than
that of A/bat/Guat/09 (Guat/164-4P), but similar to that of the
human (WSN-4P) influenza virus. In contrast, the Peru/033-4P
was 16-fold less active than Guat/164-4P with the WSN.NS-NCR
(Fig. S2) indicating a possible host restriction for the Peru/033-4P
to function efficiently with human influenza genome segments.
However, previous reports have shown that differences of this
magnitude could be determined by a single amino-acid substitu-
tion in one of the polymerase proteins [11,12].
HA and NAL protein structure
We determined crystal structures of the A/bat/Peru/10 HA
and NAL proteins expressed in a baculovirus system. Two highly
Table 2. Important functional motifs in non-bat influenza A internal proteins are largely conserved in bat influenza proteins.
Protein Position(s) Non-bat viruses A/bat/Guat/09 A/bat/Peru/10 Comment
PB2 2–4, 6–7 ERI, EL DRI, EL { Direct contact with PB1
627 E or K S E associated with avian viruses, K with mammalian
viruses
701 D or N N N associated with adaptation to mice
737–739 RKR Minor nuclear localization signal
752–755 KRIR Major nuclear localization signal
PB1 5–10 PTLLFL PMLIFL Binding to PA
444–446 SDD Catalytic activity (equivalent to GDD of positive
strand viruses)
PA 80, 108, 119 E, D, E Endonuclease catalytic domain
102, 510 K, H Cap-snatching activity
408, 412, 620, 621,
623, 670, 673, 706
Q, N, P, I, E, Q, R, W PB1 binding
NP 3–13 TxGTKRSYxxM TxGLKRTFxxM GxGTKRTFxxM Nuclear localization signal
M1 101–105 RKLKR KKLKK Nuclear localization signal
M2 31 S or N N N31 is associated with adamantane resistance
NS1 35–41 DRLRR Nuclear localization signal
103 F V CPSF30 binding/stabilization
106 M Q
138–147 FDRLETLILL FGKLERLVLA FGKVERLVLA Nuclear export signal
227–230 ESEV or absent absent PDZ ligand binding domain
NS2 12–21 ILxRMSKMQL Nuclear export signal
{Letters written as subscripts denote amino acid substitutions in bat viruses compared to the consensus non-bat amino acid sequence.
doi:10.1371/journal.ppat.1003657.t002
Bat Influenza Virus
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similar crystal structures of the A/bat/Peru/10 HA ectodomain
were independently determined to 2.15 and 2.24 A˚ resolution
(Table S6) (Ca r.m.s.d. of 0.25 A˚ and 0.34 A˚ between equivalent
monomers and trimers). The overall H18 HA trimer is similar to
other HA structures with a membrane-distal globular head
comprising the RBS and the vestigial esterase domain, and a
membrane-proximal stem region containing the putative mono-
basic HA1/HA2 cleavage site and fusion peptide (Fig. 2A, Fig. S3,
and Tables S3 and S7). The H18 HA ectodomain was expressed
in the HA0 form [13]. Tryptic digestion of HA0 at pH 8.0 resulted
in specific cleavage to HA1/HA2 (Fig. 3), suggesting A/bat/Peru/
10 HA also requires processing to be functional for infection.
Surprisingly, however, trypsin digestion at pH 4.9 did not degrade
HA1 and HA2 (Fig. 3) in contrast to other HAs that adopt a fusion
active form on exposure to pH#5.5 exposing trypsin cleavage sites
and degradation in this assay. Thus, although the fusion peptide,
coiled-coil heptad repeats, HA2 Arg106, and the stem region in
general are largely conserved, the requirements for the pH-
induced conformational change that occurs upon activation of
membrane fusion appear to be different [14,15]. The membrane-
distal domain mediates receptor binding and contains most of the
epitopes recognized by antibodies. The HAs from influenza viruses
are well documented to bind to glycan receptors with terminal
sialic acid. The RBS in influenza A contains several highly
conserved amino acids at its base: Tyr98, Trp153, His183, and
Tyr195 (H3 numbering, Tables S3 and S8), and three major
structural elements at its edge: 130-loop (134–138), 220-loop (221–
228), and 190-helix (188–194) [16,17]. In all HAs examined to
date, sialic acid binds through hydrophobic interactions and
hydrogen bonds with HA residues from the 130- and 220-loops
and 190-helix (Fig. S3C) as well as the base [18]. In contrast, H18
HA has a dramatic alteration of the binding site residues (Fig. 2B,
Tables S3 and S8) where only three (Trp153, His183, and Tyr195)
of the key RBS residues in influenza A viruses [16,19] are
conserved (Fig. 2B, Table S8), although Glu190 and Gly225
represent consensus sequences in avian HAs. Tyr98 that hydrogen
bonds to the 8-hydroxyl group of sialic acid in influenza A viruses,
is replaced in H18 by Phe98 (Table S8). Significantly, Leu194 in
influenza A and B viruses, another critical residue for sialic acid
binding [20], is replaced by Tyr194 in H18 (Table S8). Together
with other larger residues, including Asp136, Gln155, and Asp228,
which are unique to H18 and H17 HA bat proteins (Tables S3
and S8), the addition of Tyr194 dramatically flattens and widens
the RBS as compared to pandemic 2009 H1 (Fig. 2C) and other
HAs (Fig. S4). The glycerol side chain of a canonical sialic acid
would clash with Tyr194 and Asp228 (Fig. 2C). In addition,
Asp136, which is not found in H1–H16, would electrostatically
repulse the sialic acid carboxylate. Several assays were used to
investigate the binding of the H18 HA to mammalian glycans.
H18 HA exhibited no specific binding to a custom sialoside
microarray (data not shown) [9,21] or the glycan microarray of the
Consortium for Functional Glycomics (CFG) that contains 610
diverse glycans found on mammalian cells, including over 100
unique sialosides (a2-3, a2-6,, a2-8, and mixed linkages) (Fig. S5A
and Tables S9, S10) [22]. In contrast, the influenza H5 HA bound
robustly to numerous sialosides on the array (Fig. S5C). The lack
of binding to sialosides was further confirmed in a plate-based
ELISA with glycans 39-SLNLN and 69-SLNLN (Fig. S5D–E)
showing no detectable binding to either sialoside, in contrast to H5
HA. These data strongly suggest that bat H18 HA does not
recognize sialic acid receptors, and its receptor remains to be
defined.
The extensive sequence divergence of A/bat/Peru/10 NAL
from the recently characterized N10 prompted us to determine its
X-ray structure in two crystal forms at 2.68 A˚ and 3.0 A˚ (Fig. S6A,
Table S6). The N11 NAL forms a typical ‘‘box-shaped’’ tetramer,
containing six four-stranded, antiparallel b-sheets in a propeller-
like arrangement (Fig. 4A). Comparison of the A/bat/Peru/10
Figure 2. Crystal structures of A/bat/Peru/10 HA. (A) Overall structure of A/bat/Peru/10 HA. The H18 HA trimer consists of three identical
monomers with one RBS per monomer. HA1 is highlighted in green and HA2 in cyan. N-linked glycans observed in the electron density maps are
shown with yellow carbons. (B) The A/bat/Peru/10 HA putative RBS (in crystal 1, Table S6) in ribbon representation with the side chains of key binding
residues shown. The three highly conserved residues (W153, H183, and Y195) in HAs are colored with green carbon atoms, whereas nine residues that
are conserved in A/bat/Peru/10 H18 and two H17 HAs from bat influenza viruses A/little yellow-shouldered bat/Guatemala/164/2009 (H17N10)
(GU09-164) and A/little yellow-shouldered bat/Guatemala/060/2010 (H17N10) (GU10-060) are labeled in red. E190 and G225 are also conserved,
especially in avian influenza A viruses. (C) Molecular surface of the putative RBS of A/bat/Peru/10 HA compared to the RBS of 2009 H1 HA from A/
California/04/2009 (H1N1) (PDB code 3UBQ). A canonical sialic acid is modeled in the HA for comparison as observed in other HA structures. The RBS
of A/bat/Peru/10 HA is shallower and wider than 2009 H1 HA with no space for the glycerol moiety of sialic acid (indicated by the red arrow). For
comparison, figures (B) and (C) are generated in the same orientation.
doi:10.1371/journal.ppat.1003657.g002
Bat Influenza Virus
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NAL monomer with other NA structures reveals surprising
similarity despite low sequence identity (29.6%) (Fig. S6B–D and
Table S4). In addition, a calcium required for stabilization of all
known influenza A and B NA active sites [23,24] is conserved in
N11 NAL (Fig. 4A). Taken together, the N11 NAL and the N10
NAL [9] are homologous proteins characterized by highly
diverged putative active sites (Fig. 4B). Among the eight conserved
charged and polar residues that interact with substrate in all other
influenza A and B subtypes [25], only Arg118, Arg224, Glu276
are conserved (N2 numbering, Fig. 4B, Tables S5 and S11) as in
N10 NALs [9]. Arg292 and Arg371, critical for sialic acid binding,
are replaced in A/bat/Peru/10 NAL by Thr and Lys, respectively.
Furthermore, only three of eleven second-shell residues are
conserved in N11 NAL (Trp178, Ser179 and Glu425) (Fig. 4B,
Tables S5 and S11). The N11 NAL active site pocket is much
wider than other flu A and B NAs, including 1918 N1, due mainly
to 150- and 430-loop movements (Fig. 4C) [26]. The glycerol
moiety of a canonical sialic acid, as observed in other flu A and B
NA structures [26], would clash with the N11 NAL active site
(Fig. 4C). In comparison with bat N10 NAL [9], eight residues are
conserved in the putative active site (Fig. 4B, Table S11). N11
NAL catalyzes extremely low levels of sialic acid cleavage (Fig. S7)
[22] as observed for N10 NAL [9], and similar to H18 HA, N11
NAL exhibited no binding to 610 diverse natural glycans including
sialosides in a glycan microarray assay (Fig. S5B and Tables S9,
S10). Thus, neither H18 HA nor N11 NAL appears to bind sialic
Figure 3. SDS-PAGE of A/bat/Peru/10 HA0 (lanes 1 to 4) and its mature HA (lanes 5 to 8) in trypsin susceptibility assay. A/bat/Peru/10
HA with a monobasic cleavage site was expressed in its HA0 form in a baculovirus expression system. Lanes 1 and 2 show A/bat/Peru/10 native HA0
at pH 8.0 and pH 4.9, respectively, while lanes 3 and 4 show the equivalent reducing gel of HA0 treated with trypsin at pH 8.0 and pH 4.9,
respectively. Similarly, lanes 5 and 6 show A/bat/Peru/10 mature HA at pH 8.0 and pH 4.9, respectively, while lanes 7 and 8 show the equivalent
reducing gel of mature HA treated with trypsin at pH 8.0 and pH 4.9, respectively.
doi:10.1371/journal.ppat.1003657.g003
Figure 4. Crystal structures of A/bat/Peru/10 NAL. (A) Overall structure of A/bat/Peru/10 NAL with a conserved calcium binding site. The N11
NAL tetramer is viewed from above the viral surface, and consists of four identical monomers with C4 symmetry. One monomer is colored in six
different colors to illustrate the canonical b-propeller shape of six four-stranded, anti-parallel b-sheets. The putative active site is located on the
membrane-distal surface (on top of the molecule). The observed N-linked glycosylation sites are shown with attached carbohydrates. A single calcium
ion is shown in red spheres. (B) The A/bat/Peru/10 NAL putative active site (crystal form 1, Table S6) with the conserved catalytic and active site
residues in other NAs shown as well as other polar and charged residues. The six residues (R118, W178, S179, R224, E276 and E425) conserved in all
influenza NAs are colored with green carbon atoms in contrast to other putative active site residues in yellow carbon atoms, whereas eight residues
that are conserved in two bat influenza N10 and N11 NAL proteins are labeled in red. (C) Molecular surface of the active site of A/bat/Peru/10 N11
NAL and 1918 N1 NA from A/Brevig Mission/1/18 (H1N1) (PDB code 3BEQ). A canonical sialic acid is modeled in A/bat/Peru/10 NAL as in other NA
structures and appears to collide with the NA putative active site around the glycerol moiety (as indicated by the red arrow). The putative active site
pocket of A/bat/Peru/10 NAL is much wider than 1918 N1 NA. For comparison, figures (B) and (C) are generated in the same orientation.
doi:10.1371/journal.ppat.1003657.g004
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acids, suggesting they interact with receptors that have still to be
identified to retain their function of mediating entry and release of
bat H18N11 viruses.
Influenza virus infections in bats
To assess the seroprevalence of infection in South American
bat populations, we analyzed panels of sera to identify IgG
antibodies to recombinant bat influenza H18 HA (rHA) and N11
NAL (rNAL) by indirect ELISA. Specific IgG antibody titers to bat
rHA or rNAL (.1:1,000) were detected among 55 of 110 bats
from Peru (Table 1). High titers ($1:16,000) to rHA or rNAL were
detected in 11 sera (10%). A high proportion of these 55 bat sera
(21 samples) were positive for both rHA and rNAL, whereas 30
were positive for rHA only and 4 positive for rNAL only. A
selection of H18 positive sera were also tested against H17, H1
and H5 (rHAs), and no cross reactivity was detected, in agreement
with the proposed H18 subtype designation (Fig. S8). If the
immunodominance of HA in humans and swine is recapitulated
in bats, the absence of antibodies to HA in NAL-seropositive
animals suggests that bat viruses of an unknown HA subtype, in
combination with N11, may have infected these animals [27]. The
proportion of seropositive samples was highest among Artibeus in
Truenococha (25 of 28 tested, positive for rHA or rNA). Five
additional bat species also appear to be highly seropositive despite
small sample sizes (Table 1).
The high seroprevalence of bat influenza in bats from the
Loreto Department in Peru prompted analysis of 228 serum
samples from eight locations in southern Guatemala in 2009–
2010. Specific antibodies to bat H17 subtype rHA were detected
by ELISA in 86 of the 228 (38%) sera from eight bat species
(Table S12). The temporal and spatial limitations of our sampling
notwithstanding, the high seroprevalence of influenza virus
infection in multiple species suggests widespread circulation of
influenza A viruses among New World bats.
Discussion
We have characterized a new influenza virus from a flat-faced
fruit bat (Artibeus planirostris) in the Amazon River basin in northern
Peru. While our phylogenetic analysis indicated that the Peruvian
bat virus shares common ancestry with recently identified
Guatemalan H17N10 bat viruses, their genetic and phylogenetic
divergence is such that we propose that their HA and NA genes be
designated as new subtypes H18 and N11, respectively. A high
frequency of antibodies is consistent with widespread circulation of
these viruses in bat populations from the Americas.
The crystal structure and glycan array analysis of A/bat/Peru/
10 HA indicate that sialic acid is not the receptor for attachment to
host cells, consistent with similar analyses of bat NAL that showed
substitution of catalytic residues and no sialidase activity in
recombinant bat NAL preparations [9]. Hence, these data suggest
that bat influenza HA and/or NAL mediate host cell entry and
release via different receptors compared to other influenza viruses.
More generally, these discoveries highlight the functional plasticity
of influenza A viruses. In addition, attempts to propagate this
virus in mammalian and avian cell cultures have been unsuccess-
ful, although viral transcription from reporter minigenomes is
functional in human and primate cells. This complicates the
development of animal models to investigate the host range and
virulence of bat influenza viruses. Taken together, these obstacles
create significant gaps in our knowledge for assessing the potential
public health significance of these viruses. Until these problems are
resolved, serologic studies in human populations that may come in
contact with bats in Central or South America that potentially
harbor H17N10 and H18N11 influenza viruses may help inform
risk assessment efforts.
Multiple lines of evidence suggest that influenza viruses have
evolved in bats for an extended period of time: (i) in four of the
eight gene segments, genetic diversity exceeds that observed in all
other animal species combined; (ii) the divergence into multiple
HA subtypes and utilization of alternative mechanisms for sialic
acid-independent virion attachment to target cells and subsequent
release; and (iii) the widespread geographic distribution in the
Americas (Guatemala and Peru sampling sites are ,3,500 km
apart) combined with a high seroprevalence in several bat species
are indicative of an established infection, while the observation
that the bat viruses form a monophyletic group is suggestive of
sustained transmission in this species. The postulated ancient
relationship of influenza viruses with aquatic migratory birds is
consistent with the optimized parasitic relationship of the virus
with ducks, involving subclinical infections with multiple virus
subtypes as a result of efficient fecal-oral transmission. Although
necessarily preliminary in nature, the data presented here suggest
that similar ecological and evolutionary strategies may have been
exploited by the influenza A viruses of New World bats.
Materials and Methods
Ethics statement
All procedures reported herein were performed in accordance
with institutionally approved animal care and use protocols (1843
RUPMULX approved by the Centers for Disease Control and
Prevention Institutional Animal Care and Use Committee). All
aspects of the bat collections were undertaken with the approval of
the a Peru Ministry of Agriculture (permit RD-0389-2010-
DGFFS-DGEFFS) and following the American Veterinary Med-
ical Association guidelines on euthanasia and the Guidelines of the
American Society of Mammalogists for the use of wild mammals
in research.
Sample collection
CDC field sampling of selected mammals, such as bats, has been
ongoing for several years as a means of background zoonotic
surveillance for primary pathogen detection [28]. Field work was
related to a reported high incidence of vampire bat depredation to
human communities in the Peruvian Amazon [29]. Bat sampling
was conducted for enhanced rabies surveillance related to
concurrent human surveys, and to improve an understanding
of pathogen diversity in the Neotropical bat fauna. Bats were
captured manually and by using mist nets and hand nets; adults
and subadults of both sexes were captured. Bats were restrained,
sedated, euthanized, and a complete necropsy was performed in
compliance with established field protocols. A total of 114 bats
from at least 18 different species were captured from Truenococha
and Santa Marta, two communities in the Loreto Department
of Peru at the edge of the Amazon River basin (Fig. S1).
Representative tissues were removed from bats. Samples of serum,
tissues, organs, rectal and oral swabs were immediately stored in
liquid nitrogen in the field and then at 280uC in the laboratory
until shipment to CDC for processing and analysis. Total nucleic
acids (TNA) were extracted from 200 mL of a phosphate buffered
saline suspension of each swab by using the QIAamp MinElute
Virus Spin kit (QIAGEN, Santa Clarita, CA), according to the
manufacturer’s instructions and then stored at 280uC.
Pan-influenza reverse transcriptase PCR
TNA extracted from the rectal swabs (n = 110) were screened
for the presence of influenza virus RNA using pan-influenza
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(pan-Flu) reverse transcriptase PCR (RT-PCR) as described
previously [2]. Positive and negative RT-PCR controls containing
standardized viral RNA extracts and nuclease-free water were
included in each run. Standard precautions were taken to avoid
cross-contamination of samples before and after RNA extraction
and amplification. Each of the positive results was repeated and
confirmed from different TNA aliquots of the original bat rectal
swab eluate. The resulting PCR amplicons were separated by
electrophoresis in agarose gel and purified using QIAquick PCR
Purification kit or QIAquick Gel Extraction kit (Qiagen, Santa
Clarita, CA). Purified DNA amplicons (both strands) were then
sequenced with the pan-Flu RT-PCR primers on an ABI Prism
3130 automated capillary sequencer (Applied Biosystems).
Complete genome sequencing
The pan-Flu RT-PCR positive rectal swab suspension was
subjected to both high throughput next generation sequencing and
RT-PCR amplicon-based Sanger sequencing as described previ-
ously [2]. In brief, 200 ml of rectal swab suspension (in PBS) from
the bat PEBT033 was first cleared through a 0.22-mm Ultrafree-
MC filter (Millipore) and then extracted using the QIAamp
MinElute Virus Spin kit. The extracted TNA was randomly
amplified using the Round AB protocol as previously described
[2]. Amplification products were subjected to high-throughput
sequencing by an Illumina GAIIx (Illumina) at Emory University.
The resulting sequence was extracted and de-multiplexed using
Illumina SCS2.8 software. The data were then analyzed using the
CLC Genomics Workbench package. The imported reads were
trimmed to remove low quality sequence as well as any reads of
#36 bases in length. The reads were assembled de novo with a
minimum contig length of 75 bases. All contigs with a coverage
depth $3X where submitted to BLASTn against the non-
redundant (nr) NCBI database to identify influenza sequences.
This process was repeated with tBLASTx to find segments that
were not identified from nucleotide BLASTn. To increase the
reliability of the sequence data from Illumina sequencing, the
rectal swab of bat PEBT033 was also processed by Sanger
sequencing on RT-PCR amplicons of genome segment. The viral
genome was amplified directly from the TNA extracted from bat
PEBT033 rectal swab suspensions using universal influenza A
primers (FWuni12 and RVuni13) [30]. The 800 bp to 2.3 kb
amplicons were then cloned using the pCR-XL-TOPO TA
cloning kit (Invitrogen). Eight to 16 colonies from each of the 8
segments’ RT-PCR transformation were first sequenced with M13
forward and reverse primers in both directions, and the remaining
internal gaps were sequenced with sequence-specific walking
primers in both directions. The 39 end and 59 end sequences of
each segment from bat PEBT033 were determined using the 59/39
RACE kit (Roche) according to the manufacturer’s instructions.
Sequence analysis and generation of contigs were performed using
Sequencher software. Consensus gene sequences were compared
to those from the high throughput next generation sequencing
methods. Sequence identification was performed through NCBI
BLASTn and tBLASTx similarity searches.
Sequence data set
8486 complete genome sequences of influenza A virus,
comprising both avian and other mammalian hosts, were
downloaded from the GISAID database (http://platform.gisaid.
org/epi3/frontend). Sequence alignment was performed on the
amino-acid sequences of each gene segment using MAFFT v6.853b
[31,32]. Because of the highly divergent nature of the HA and NAL
segments, all ambiguously aligned sites in these segments were
removed using the Gblocks program [33]. This resulted in final
alignment lengths for the HA and NAL proteins of 507 and 395
amino acids, respectively. Because of the very large number of
sequences available from some subtypes, each amino acid
alignment was further subsampled based on sequence similarity
to obtain smaller data sets containing between 300 and 400
representative sequences. Pairwise genetic distances were then
estimated between these sequences using the JTT model of amino
acid substitution available in the MEGA5 v5.05 package [34].
Phylogenetic analyses
To assist our phylogenetic analyses of these sequence data, we
further reduced the sample size to 50–70 representative sequences
for each gene segment. Phylogenetic trees of these data were then
estimated using the maximum likelihood (ML) method available in
the PhyML package [35], employing 100 bootstrap replicates. In
all cases, the JTT model of amino acid substitution was employed
with four categories of gamma-distributed rate heterogeneity and a
proportion of invariant sites (JTT+C4+I).
ELISA assay
An indirect ELISA using bat influenza neuraminidase and
hemagglutinin was run to establish the seroprevalence of IgG
antibodies to bat influenza within the Peru bat population. In
brief, ELISA plates were coated with recombinant bat hemagglu-
tinin (rHA18, rHA17), recombinant avian hemagglutinin (rHA5
and rHA1), or recombinant bat neuraminidase-like (rNAL) at a
concentration of 1 mg/mL (100 mL per well) in PBS, pH 7.4
overnight at 4uC. The next morning, bat sera were heat
inactivated at 56uC for 30 minutes. Plates were washed 3 times
with PBS with Tween 20 (0.1%), pH 7.4 (PBST). Bat sera were
diluted 1:500 in 2.5% non-fat milk-PBST and added to each well
in duplicate, two-fold dilutions. Plates were incubated for 1 hour
at 37uC. The test sera were removed and the plates washed 3 times
with PBST. Biotinylated protein G (MBL corp) (a 1:1,000 dilution
of 1 mg/mL solution, 100 mL) was added to each well and the
plates were incubated at 37uC for 1 hour. The plates were washed
3 times with PBST. Streptavidin HRP (Millipore) (a 1:10,000
dilution of 1 mg/mL solution, 100 mL) was added to each well and
the plates were incubated at 37uC for 1 hour. The plates were
washed 3 times with PBST and O-phenylenediamine (OPD), with
H2O2 and phosphate-citrate buffer, was added to each well
(100 mL). The plates were incubated at 37uC for 10 minutes, the
color change was stopped by addition of 100 uL of 3N HCl, and
the plates read by a plate reader. The limit of detectable response
(based on 490 nm at 0.1 s OD) for the ELISA was set as values
above average background plus 2 standard deviations.
Cloning, expression and purification of A/bat/Peru/10
H18 HA protein used for crystal 1
The ectodomain (residues 15-513, equivalent to 11-329 of HA1
and 1-174 of HA2 in H3 numbering) of the H18 protein from
influenza virus A/flat-faced bat/Peru/033/2010 (H18N11, Gen-
Bank accession number CY125945) was expressed in a baculovirus
system for structural and functional analyses. The cDNA corre-
sponding to the H18 HA ectodomain was inserted into a
baculovirus transfer vector, pFastbacHT-A (Invitrogen) with an
N-terminal gp67 signal peptide, a C-terminal thrombin cleavage
site, a foldon trimerization sequence, and a His6-tag [21]. The
constructed plasmids were used to transform DH10bac competent
bacterial cells by site-specific transposition (Tn-7 mediated) to form
a recombinant Bacmid with beta-galactosidase blue-white receptor
selection. The purified recombinant bacmids were used to transfect
Sf9 insect cells for overexpression. The HA protein was produced by
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infecting suspension cultures of Hi5 cells with recombinant
baculovirus at an MOI of 5–10 and incubated at 28uC shaking at
110 RPM. After 72 hours, Hi5 cells were removed by centrifugation
and supernatants containing secreted, soluble HAs were concen-
trated and buffer-exchanged into 20 mM Tris pH 8.0, 300 mM
NaCl, further purified by metal affinity chromatography using Ni-
nitrilotriacetic acid (NTA) resin (Qiagen), For crystal structure
determination, the HA ectodomain was digested with thrombin to
remove the foldon domain and His6-tag. The cleaved trimeric H18
HA ectodomain was purified further by size exclusion chromatog-
raphy on a Hiload 16/90 Superdex 200 column (GE healthcare) in
20 mM Tris pH 8.0, 100 mM NaCl and 0.02% NaN3.
Cloning, expression and purification of A/bat/Peru/10
N11 NAL protein used for crystal form 1
The cDNA corresponding to the ectodomain of A/bat/Peru/10
NAL (residues 83-448, equivalent to 81-459 in N2 numbering)
from influenza virus A/flat-faced bat/Peru/033/2010 (H18N11,
GenBank accession number CY125947) was cloned into the
baculovirus transfer vector pAcGP67-B, in frame with an N-
terminal cassette containing a His6-tag, a vasodilator-stimulated
phosphoprotein (VASP) domain and thrombin cleavage site [36].
Transfection and virus amplification were carried out as described
previously [10]. Protein expressed from Sf9 cells (Invitrogen) in 3-
liter shaking flasks (Corning Inc.) was recovered from the culture
supernatant and purified by metal affinity chromatography,
subjected to thrombin cleavage and gel filtration chromatography.
The purified monomeric N11 NAL protein was buffer exchanged
into 10 mM Tris-HCl, 50 mM NaCl, pH 8.0 with 1 mM CaCl2
and concentrated to 14 mg/ml for crystallization trials.
Crystal structure determination of A/bat/Peru/10 H18 HA
in crystal 1
Crystallization experiments were set up using the sitting drop
vapor diffusion method. The A/bat/Peru/10 HA ectodomain
trimer protein at 14 mg/ml in 20 mM Tris pH 8.0, 100 mM
NaCl and 0.02% (w/v) NaN3 was crystallized in 0.1 M MES,
pH 6.9, 5% (w/v) polyethylene glycol (PEG) 1000 and 27.5% (w/
v) PEG 600 at 22uC. The A/bat/Peru/10 HA crystals were
flashed-cooled at 100 K without additional cryo-protectant.
Diffraction data were collected at beamline 23ID-D at the
Advanced Photon Source (APS) (Table S6). Data for all crystals
were integrated and scaled with HKL2000 [37].
The A/bat/Peru/10 HA structure was determined by molec-
ular replacement (MR) using the program Phaser [38] with A/
bat/Peru/10 HA from its crystal structure in complex with an
antibody Fab as the search model. This Fab complex structure was
previously determined using A/South Carolina/1/18 (H1N1) H1
HA (PDB code 1RD8) as the MR search model and will be
published elsewhere. Initial rigid body refinement of A/bat/Peru/
10 HA was performed in Refmac5 [39], and simulated annealing
and restrained refinement (including TLS refinement) were
carried out in Phenix [40]. Between rounds of refinements, model
building was carried out with the program Coot [41]. Final data
processing and refinement statistics are represented in Table S6.
The quality of the structure was determined using the JCSG
validation suite (www.jcsg.org). All figures were generated with
Bobscript [42] except for Figs. 2C and 2F, Figs. S3 and S4, which
used PyMol (www.pymol.org).
Protease susceptibility assay
Each trypsin cleavage reaction containing ,2.5 mg of A/bat/
Peru/10 HA0 or trypsin-digested A/bat/Peru/10 mature HA
(HA1/HA2) and 1% dodecylmaltoside (to prevent possible
aggregation with any post-fusion HA) was set up at room
temperature (,22uC). Sodium acetate was used as the pH 4.9
buffer and Tris was used as the pH 8.0 buffer. Reactions were
thoroughly mixed, centrifuged at .12,000 g for 30 seconds and
allowed to incubate at 37uC for one hour. After incubation,
reactions were equilibrated to room temperature and the pH was
neutralized by addition of 200 mM Tris, pH 8.5. Trypsin was
added to all samples, except controls, at a final ratio of 1:1 (w/w)
for A/bat/Peru/10 HA. Samples were digested overnight
(,18 hours) at 22uC. Reactions were quenched by addition of
non-reducing or reducing SDS buffer and were boiled for,2 min.
Samples were analyzed by SDS-PAGE.
Crystal structure determination of A/bat/Peru/10 N11
NAL in crystal form 1
Initial crystallization trials were set up using a TopazTM Free
Interface Diffusion (FID) Crystallizer system (Fluidigm Corpora-
tion). Crystals were observed in conditions containing various
molecular weights of PEG polymer. Following optimization,
diffraction quality crystals for A/bat/Peru/10 N11 NAL were
obtained at 20uC using a sitting drop method. The crystallization
condition was 0.2 mM calcium acetate, 10% (w/v) PEG 8000, 0.1
M HEPES at pH 7.5. Crystals were flash-cooled at 100 K using
20% (v/v) glycerol as a cryoprotectant. Data were collected at the
Advanced Photon Source (APS) beamline 22-ID at 100 K and
processed with the DENZO-SCALEPACK suite [37].
The structure of A/bat/Peru/10 NAL was determined by
molecular replacement with Phaser [38] using the N10 NAL
structure from A/little yellow-shouldered bat/Guatemala/164/
2009 (H17N10) (PDB code 4GEZ) as the search model (sequence
identity is 40%). Four neuraminidase monomers were found that
constituted one non-crystallographic tetramer with an estimated
solvent content of 63.6% based on a Matthews’ coefficient (Vm) of
3.38 A˚3/Da. The model was rebuilt by Coot [41] and structure
refined with Refmac5 [43]. The final model was assessed using
MolProbity [44]. Statistics on data processing and refinement are
presented in Table S6.
Cloning, expression, purification, and crystal structure
determination of A/bat/Peru/10 surface proteins in
crystal form 2
Methods used for H18 HA and N11 NAL proteins used for
crystal form 2 were as described (see Text S1).
Neuraminidase activity assay with substrate 4-MU-NANA
NA enzymatic activities were measured by using fluorescent
substrate 29-(4-methylumbelliferyl)-a-D-N-acetylneuraminic acid
(4-MU-NANA) [45] in 100 mM imidazole-malate pH 6.15,
150 mM NaCl, 10 mM CaCl2 0.02% NaN3 buffer with excitation
and emission wavelengths of 365 nm and 450 nm, respectively.
The reaction was conducted for 60 minutes at 37uC in a total
volume of 80 ml for the N11 NAL protein with ectodomain plus
stalk region that was expressed as a tetramer. The reactions were
all performed in triplicate and were stopped by adding 80 ml of 1
M Na2CO3. To compare NA cleavage activities at 12 different NA
concentrations, with a fixed substrate 4-MU-NANA concentration
of 0.05 mM, the NA starting solution at 0.51 mg/ml was serially
diluted 1:2.
Data sharing
The sequence data reported in this paper were deposited in
the GenBank database at NCBI under accession numbers
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CY125942-CY125949. The atomic coordinates and structure
factors of the A/bat/Peru/10 H18 crystals 1 and 2, and A/bat/
Peru/10 N11 in crystal forms 1 and 2 are being deposited in the
Protein Data Bank, www.rcsb.org (PDB ID codes 4K3X, 4MC5,
4MC7 and 4K3Y).
Supporting Information
Figure S1 Geographic locations of bat-sampling sites in Peru.
Bats were captured at Truenococha and Santa Marta in the
Loreto District (the inset depicts this region within the Republic of
Peru, see Table 1 and Table S1 for additional information).
(PDF)
Figure S2 RNA-dependent RNA polymerase activity of A/bat/
Peru/10 ribonucleoprotein (RNP) complex proteins (PB2, PB1,
PA and NP). A549 human lung cells were transfected with
pPol1-A/bat-NS.NCR-Renilla (Guat/164.NS-NCR) or pPol1-A/
WSN-NS.NCR-Renilla (WSN.NS-NCR) and pSV40-Luc reporter
plasmids, together with plasmids expressing PB2, PB1, PA and NP
from either A/WSN/33 (WSN-4P) or A/bat/Peru/10 (Peru/033-
4P) or A/bat/Guat/09 (Guat/164-4P) viruses or without the PB1
expression plasmid (Guat/164-3P). Values shown represent the
activities of each RNP and reporter relative to that of WSN virus
(100%) with the homologous reporter. Error bars indicate 95%
confidence intervals. Experiments were performed three times
independently.
(PDF)
Figure S3 The structure of A/bat/Peru/10 HA in crystal 2. (A)
One monomer is shown with the HA1 chain colored in green and
the HA2 chain in cyan. The glycosylation positions are highlighted
in magenta with the glycan in yellow. A/bat/Peru/10 HA has four
potential N-linked glycosylation sites in HA1 (Asn21, Asn242,
Asn264, Asn289) and a further two in HA2 (Asn145 and Asn154).
While position 21 is close to the HA1/HA2 cleavage site, position
242 is closer to the putative receptor binding pocket. Positions 264
and 289 are close together in the middle of the molecule around
the vestigial esterase domain in HAs from other influenza A
viruses. In the HA2, positions 145 and 154 are near the
membrane-anchoring region. Asn154 is conserved in all HAs,
while Asn145 is only found in HA sequences from three other
group 1 subtypes (H13, H16 and H17). From these structures,
interpretable electron density for one or two N-acetyl glucos-
amines was observed at all six of these putative glycosylation sites.
However, due to crystal packing, density for the carbohydrate at
Asn242 was well defined in all three monomers and could be
visualized up to the first three mannoses of the glycan. (B) The
putative receptor binding site with the three structural elements,
the 130-loop, 220-loop and the 190-helix. The putative binding
site residues are shown in sticks. (C) Superposition of receptor
binding site region of A/bat/Peru/10 H18 (in green), 1918 H1 (in
salmon, PDB code 1RD8), 2009 H1 (in purple, 3M6S), swine H1
(in pink, 4F3Z), human H2 (in grey, 2WR7), human H5 (in yellow,
2FK0), swine H9 (in orange, 1JSD), human H3 (in cyan, 2HMG),
human H7 (in marine, 4DJ6) and mallard H14 (in slate, 3EYJ).
(PDF)
Figure S4 Comparative surface representation of the receptor
binding sites of bat and non-bat HAs. A/bat/Peru/10 H18 HA (in
green), 1918 H1 HA (salmon, PDB code 1RD8), 2009 H1 HA
(purple, 3M6S), swine H1 HA (pink, 4F3Z), H2 HA (grey, 2WR7),
H5 HA (yellow, 2FK0), H9 (orange, 1JSD), H3 HA (cyan,
2HMG), H7 HA (marine, 4DJ6) and H14 HA (slate, 2EYJ), with
arrows indicating the receptor binding sites in other HAs.
(PDF)
Figure S5 Glycan binding analysis of A/bat/Peru/10 HA and
NAL. (A to C) Glycan microarray analysis of A/bat/Peru/10 HA
(A) and NAL (B), and control protein A/Vietnam/1203/2004 H5
HA (C) was performed on the CFG glycan microarray v5.1, which
contains 610 mammalian glycans. Binding signals (black bars) are
shown in relative fluorescence units (RFU). The H5 HA showed
good binding avidity to a2-3 glycans, but A/bat/Peru/10 HA and
NAL exhibit no specific binding to any glycans on the array,
including natural sialosides with a2-3, a2-6, a2-8 and mixed
linkages, and other glycans that might exist in mammals (see Tables.
S9 and S10). (D to E) ELISA-based plate assay of A/bat/Peru/10
HA and control A/Vietnam/1203/2004 H5 to 39-SLNLN (D) and
69-SLNLN (E). The H18 HA does not bind to either 39-SLNLN or
69-SLNLN in the experimental conditions, while the control H5
HA binds more strongly to 39-SLNLN as expected.
(TIF)
Figure S6 Stereo view of superimposed A/bat/Peru/10 NAL in
crystal form 1 (in grey) with other NA structures. (A) Comparison
with A/bat/Peru/10 NAL in crystal form 2 (in green) with Ca
r.m.s.d. of 0.7 A˚. The structures of A/bat/Peru/10 NAL in two
crystal forms are the same except for the 150-loop, which is
flexible in crystal form 2 and not modeled. (B) Comparison with
GU09-164 NAL in crystal form 1 (in sky blue, PDB code 3GDI)
with r.m.s.d. of 1.3 A˚. The overall structures are very similar
except for 150-loop which is closer to the putative active site in A/
bat/Peru/10 N11 NAL, making the putative active site less open.
(C) Comparison with GU09-164 NAL in crystal form 2 (in
magenta, PDB code 3GEZ) with Ca r.m.s.d. of 1.2 A˚. The overall
structures are very similar except for 150-loop which is further
from the putative active site in A/bat/Peru/10 N11 NAL, making
the putative active site more open. (D) Comparison with 1918 N1
NA (in purple, PDB code 3BEQ) with Ca r.m.s.d. of 1.7 A˚. As
large conformational changes are observed in the 110-loop, 150-
loop and 430-loop, as well as C-terminus, these regions were
excluded from the RMSD calculation. Compared to 1918 N1 NA,
the A/bat/Peru/10 NAL putative active site in crystal form 1
adopts a much more open conformation.
(PDF)
Figure S7 NA cleavage activity analysis of A/bat/Peru/10
NAL. Only extremely low sialic acid cleavage activity was
observable with NAL concentrations as high as 100 mg/ml.
(PDF)
Figure S8 Detection of antibody to HA subtypes in bat sera by
ELISA. Plates were coated with 1 ug/mL of H18 rHA antigen
(homologous), or H17, H5,H1 rHA antigen (heterologous) to
ascertain levels of cross reactivity. Serial log2 dilutions of sera were
performed, starting at 1:500, and an absorbance reading was taken
at 490 nm for 0.1 seconds. Samples represented are (A) Peru 017,
(B) Peru 019, (C) Peru 020, and (D) Peru 031.
(PDF)
Table S1 Nucleotide sequence identity between A/flat-faced
bat/Peru/033/2010 (H18N11) and A/little yellow-shouldered
bat/Guatemala/164/2009 (H17N10) genomes.
(DOCX)
Table S2 Mean amino acid identity between A/bat/Peru/10
H18 HA and influenza A subtypes H1–H17.
(DOCX)
Table S3 Sequence comparison after sequence and structural
alignment of HA1 (top) and HA2 (bottom) of A/bat/Peru/10 H18
HA with bat H17 HAs and non-bat HAs a.
(DOCX)
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Table S4 Mean amino acid identity between the A/bat/Peru/
10 N11 NAL and representative NAs of influenza A and B viruses.
(DOCX)
Table S5 Sequence comparison of A/bat/Peru/10 N11 NAL
with bat N10 NALs and other influenza NAsa.
(DOCX)
Table S6 Data collection and refinement statistics of A/bat/
Peru/10 HA and A/bat/Peru/10 NAL.
(DOCX)
Table S7 Comparison of Ca rmsd values (A˚) of A/bat/Peru/10
HA (crystal 1) with other influenza A virus HAsa.
(DOCX)
Table S8 Conservation of key residues in influenza A HA
receptor-binding site a.
(DOCX)
Table S9 List of glycans on the microarray.
(XLS)
Table S10 List of 25 glycans that give strongest binding signals
in the microarray.
(XLSX)
Table S11 Conservation of key residues in the NA active site.
(DOCX)
Table S12 Seroprevalence of IgG in Guatemalan bats to H17
rHA by ELISA.
(DOCX)
Text S1 Supporting Text. Methods, figure legends and tables.
(DOCX)
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Table S1. Nucleotide sequence identity between A/flat-faced 
bat/Peru/033/2010 (H18N11) and A/little yellow-shouldered 
bat/Guatemala/164/2009 (H17N10) genomes 
A/bat/Peru/10 gene % identity with A/bat/Guat/164/09  
PB2 76.5 
PB1 76.2 
PA 78.3 
HA 62.3 
NP 78.9 
NA 48.7 
M 81.6 
NS 78.9 
 
 Table S2. Mean amino acid identity between A/bat/Peru/10 H18 HA and influenza A subtypes H1-H17 
   
Group 1 Group 2 
All HAs 
(average) 
 HA  A/bat/Peru/10 H18 HA H1 H2 H5 H6 H17 H11 H13 H16 H8 H9 H12 
 Average 
Group 1 H3 H4 H14 H7 H10 
Average 
Group 2 
 
G
ro
up
 1
 
H1 50.2                         
              
H2 52.9 65.0                       
              
H5 54.5 63.0 75.9                     
              
H6 50.0 59.1 58.5 60.4                   
              
H17 60.2 51.8 54.4 53.6 52.3                 
              
H11 46.0 53.9 54.7 57.0 55.0 46.5               
              
H13 45.5 50.2 50.3 51.2 51.2 45.6 59.1             
              
H16 
45.0 51.2 49.8 50.8 48.7 45.2 59.3 81.6                         
H8 
46.1 51.0 48.5 50.3 53.7 48.3 48.9 48.1 49.5                       
H9 
46.0 50.9 51.6 50.8 54.5 48.4 52.4 51.2 49.6 62.5                     
H12 
43.8 47.4 48.9 48.8 51.2 45.5 48.9 49.3 49.6 64.3 65.3                   
Average 
Group 1 49.1 
  
53.5 
      
G
ro
up
 2
 
H3 
36.3 42.1 41.4 42.5 42.0 36.6 39.6 37.7 37.9 41.4 40.7 40.3                 
H4 
37.6 42.3 42.5 41.8 42.2 37.3 41.2 40.8 40.4 44.6 43.2 42.5   64.1             
H14 
38.1 42.6 42.0 43.1 43.2 38.9 41.4 43.3 41.9 43.3 42.6 41.1   64.8 77.9           
H7 
39.5 43.2 41.5 42.2 41.7 38.3 41.1 39.4 38.4 40.0 39.3 41.0   46.9 47.2 48.1         
H10 
37.5 44.1 42.9 42.1 42.9 36.8 42.7 41.0 40.0 41.8 41.2 40.8   49.5 50.0 49.6 61.8       
H15 
40.1 43.4 41.4 40.9 42.3 37.5 41.9 40.0 38.6 40.4 39.7 40.9   47.1 48.2 49.7 80.0 65.2     
Average 
Group 2 38.2 
      
56.7 
  
All HAs 
(average) 45.3   47.8 
 
Table S3. Sequence comparison after sequence and structural alignment of HA1 (top) and HA2 (bottom)  
of A/bat/Peru/10 H18 HA with bat H17 HAs and non-bat HAs a 
________________________________________________________________ 
                                         1       10        20        30         40        50  54 
A/bat/Peru/10 H18 -------------MITILILVLP--IVVG----DQICIGYHSNNSTQTVNTLLESNVPV-TSSHSILEKEHNGLLCKL 
GU09-164[H17N10]  -----------MELIVLLILLNPYTFVLG----DRICIGYQANQNNQTVNTLLEQNVPV-TGAQEILETNHNGKLCSL 
GU10-060[H17N10]  -----------MELIILLILLNPYTFVLG----DRICIGYQANQNNQTVNTLLEQNVPV-TGAQEILETNHNGKLCSL                                                         
SC18 [H1N1]       ------------MEARLLVLLCAFAATNA----DTICIGYHANNSTDTVDTVLEKNVTV-THSVNLLEDSHNGKLCKL 
HK68[H3N2]        -------MKTIIALSYIFCLALGQDLPGNDNSTATLCLGHHAVPNGTLVKTITDDQIEV-TNATELVQSSSTGKICNN 
B/HK73            -------MKAIIVLLMVVTSN-----------ADRICTGITSSNSPHVVKTATQGEVNVTGVIPLTTTPTKSHFANLK 
                 55    60             70        80         90        100         110        120 
A/bat/Peru/10 H18 KGKAPLDL-----IDCSLPAWLMGNPKCDELLTASEWAYIKEDPEPENGICFPG-DF-DSLEDLILLVSNTDHFR-KE 
GU09-164[H17N10]  NGVPPLDL-----QSCTLAGWLLGNPNCDSLLEAEEWSYIKINESAPDDLCFPG-NF-ENLQDLLLEMSGVQNFT-KV 
GU10-060[H17N10]  NGVPPLDL-----QSCTLAGWLLGNPNCDNLLEAEEWSYIKINENAPDDLCFPG-NF-ENLQDLLLEMSGVQNFT-KV 
SC18 [H1N1]       KGIAPLQL-----GKCNIAGWLLGNPECDLLLTASSWSYIVETSNSENGTCYPG-DF-IDYEELREQLSSVSSFE-KF 
HK68[H3N2]        P-HRILDG-----IDCTLIDALLGDPHCDVFQN-ETWDLFVERSKAFSN-CYPY-DV-PDYASLRSLVASSGTLE-FI 
B/HK73            G-TQTRGKLCPNCLNCTDLDVALGRPKCMG-TIPSAKASILHEVKPVTSGCFPIMHDRTKIRQLPNLLRGYENIRLSA  
                122          130        140        150       160        170         180      189 
A/bat/Peru/10 H18 KIID-MTRFS--DVTTN-NVDSACPYDTNGASFYRNLNWVQQ--NKGKQ-LIFHYQNSEN--NPLLIIWGVHQTSNAA 
GU09-164[H17N10]  KLFN-PQSMT--GVTTN-NVDQTCPFE-GKPSFYRNLNWIQG--NSGLP-FNIEIKNPTS--NPLLLLWGIHNTKDAA 
GU10-060[H17N10]  KLFN-PQSMT--GVTTN-NVDQTCPFE-GKPSFYRNLNWIQG--NSGLP-FNIEIKNPTS--NPLLLLWGIHNTKDAA 
SC18 [H1N1]       EIFPKTSSWP--NHETTKGVTAACSYA-GASSFYRNLLWLTKKGSSYPK-LSKSYVNNKG--KEVLVLWGVHHPPTGT 
HK68[H3N2]        TEGF---TWT--GVTQN-GGSNACKRG-PGNGFFSRLNWLTKSGSTYPV-LNVTMPNNDN--FDKLYIWGVHHPSTNQ 
B/HK73            RNVTNAETAPGGPYIV--GTSGSCPNVTNGNGFFATMAWAVPKNKTATNPLTVEVPYICTKGEDQITVWGFHSD-DET  
                190        200       210        220           230       240       250       260      
A/bat/Peru/10 H18 EQNTYYGSQT-GSTTITIGEETNTYPLVISE-SSI---LNG-HSDRINYFWGVVNPNQNFSIVSTGNFIWPEYGYFFQ 
GU09-164[H17N10]  QQRNLYGNDY-SYTIFNFGEKSEEFRPEIGQ-RDE---VKA-HQDRIDYYWGSLPAQSTLRIESTGNLIAPEYGFYYK 
GU10-060[H17N10]  QQRNLYGNDY-SYTIFNFGEKSEEFRPDIGQ-RDE---IKA-HQDRIDYYWGSLPAQSTLRIESTGNLIAPEYGFYYK 
SC18 [H1N1]       DQQSLYQNAD-AYVSVGSSKYNRRFTPEIAA-RPK---VRD-QAGRMNYYWTLLEPGDTITFEATGNLIAPWYAFALN 
HK68[H3N2]        EQTSLYVQES-GRVTVSTRRSQQSIIPNIGS-RPW---VRG-QSSRISIYWTIVKPGDVLVINSNGNLIAPRGYFKMR 
B/HK73            QMVKLYGDSKPQKFTSSANGVTTHYVSQIGGFPNQAEDEGLPQSGRIVVDYMVQKPGKTGTIAYQRGVLLPQKVWCAS  
                262       270       280        290        300       310       320          329  
A/bat/Peru/10 H18 KTTNISGIIKSSEKISDCDTICQTK-IGAINSTL-PFQNIHQNAIGDCPKYVKAQELVLATGL--RNNP--IKETR 
GU09-164[H17N10]  RKEGKGGLMKSKLPISDCSTKCQTP-LGALNSTL-PFQNVHQQTIGNCPKYVKATSLMLATGL--RNNP--QMEGR 
GU10-060[H17N10]  RKEGKGGLMKSKLPISDCSTKCQTP-LGALNSTL-PFQNVHQQTIGNCPKYVKATSLMLATGL--RNNP--QMEGR 
SC18 [H1N1]       RG-SGSGIITSDAPVHDCNTKCQTP-HGAINSSL-PFQNIHPVTIGECPKYVRSTKLRMATGL--RNIP--SIQSR 
HK68[H3N2]        TG-K-SSIMSSDAPIDTCISECITP-NGSIPNDK-PFQNVNKITYGACPKYVKQNTLKLATGM--RNVP--EKQTR 
B/HK73            GR-S-KVIKGSLPLIG-EAD-CLHEKYGGLNKSKPYYTGEHAKAIGNCPIWVKT--PLKLANGTKYRPPAKLLKER  
 
                  1       10        20        30        40        50        60        70      78 
A/bat/Peru/10 H18 GLFGAIAGFIEGGWQGLIDGWYGYHHQNSEGSGYAADKEATQKAVDAITTKVNNIIDKMNTQFESTAKEFNKIEMRIK 
GU10-060[H17N10]  GLFGAIAGFIEGGWQGMIDGWYGYHHENQEGSGYAADKEATQKAVDAITNKVNSIIDKMNSQFESNIKEFNRLELRIQ                                               
GU09-164[H17N10]  GLFGAIAGFIEGGWQGMIDGWYGYHHENQEGSGYAADKEATQKAVDAITNKVNSIIDKMNSQFESNIKEFNRLELRIQ 
SC18 [H1N1]       GLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAIDGITNKVNSVIEKMNTQFTAVGKEFNNLERRIE 
HK68[H3N2]        GLFGAIAGFIENGWEGMIDGWYGFRHQNSEGTGQAADLKSTQAAIDQINGKLNRVIEKTNEKFHQIEKEFSEVEGRIQ 
B/HK73            GFFGAIAGFLEGGWEGMIAGWHGYTSHGAHGVAVAADLKSTQEAINKITKNLNSLSELEVKNLQRLSGAMDELHNEIL 
                                         defgabcdefgabcdefgabcdefgabcdefgabcdefgabcdefgabcdefgab 
                  80        90       100       110       120       130       140       150   156  
A/bat/Peru/10 H18 HLSDRVDDGFLDVWSYNAELLVLLENERTLDFHDANVNNLYQKVKVQLKDNAIDMGNGCFKILHKCNNTCMDDIKNGT 
GU10-060[H17N10]  HLSDRVDDALLDIWSYNTELLVLLENERTLDFHDANVKNLFEKVKAQLKDNAIDEGNGCFLLLHKCNNSCMDDIKNGT 
GU09-164[H17N10]  HLSDRVDDALLDIWSYNTELLVLLENERTLDFHDANVKNLFEKVKAQLKDNAIDEGNGCFLLLHKCNNSCMDDIKNGT 
SC18 [H1N1]       NLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVRNLYEKVKSQLKNNAKEIGNGCFEFYHKCDDACMESVRNGT 
HK68[H3N2]        DLEKYVEDTKIDLWSYNAELLVALENQHTIDLTDSEMNKLFEKTRRQLRENAEDMGNGCFKIYHKCDNACIESIRNGT 
B/HK73            ELDEKVDDLRADTISSQIELAVLLSNEGIINSEDEHLLALERKLKKMLGPSAVDIGNGCFETKHKCNQTCLDRIAAGT 
                  cdefgabcdefgabcdefgabcdefgabcdefgabcdefgabcdefgabcdefga 
                   160       170   175 
A/bat/Peru/10 H18 YNYYEYRKESHLEK-QKID 
GU10-060[H17N10]  YKYMDYREESHIEK-QKIDG 
GU09-164[H17N10]  YKYMDYREESHIEK-QKIDG 
SC18 [H1N1]       YDYPKYSEESKLNR-EEIDG 
HK68[H3N2]        YDHDVYRDEALNNR-FQIKG 
B/HK73            FNAGEFSLPTFDSLNITAAS            
________________________________________________________________ 
a Abbreviations: A/bat/Peru/10, A/flat-faced fruit bat/Peru/033/2010 (H18N11); GU10-060, A/little yellow-shouldered 
bat/Guatemala/060/2010 (H17N10); GU09-164, A/little yellow-shouldered bat/Guatemala/164/2009 (H17N10); SC18, 
A/South Carolina/1/18 (H1N1); HK68, A/Hong Kong/68 (H3N2); B/HK73, B/Hong Kong/8/73. Green indicates 
important residues around the receptor-binding site in all flu A HAs [16]. The putative fusion peptide in A/bat/Peru/10 
HA is colored red and highly conserved with all other HAs. The conservation of the heptad repeats of HA2 and their 
positions in the coil (a-g) are shown in yellow and cyan. 
Table S4. Mean amino acid identity between the A/bat/Peru/10 N11 NAL and representative NAs of 
influenza A and B viruses 
 
NA subtype A/bat/Peru/10  N11  N1 N2 N3 N4 N5 N6 N7 N8 N9 N10 
 
N1 31.0                     
 
N2 25.0 45.2                   
 
N3 23.6 46.2 51.6                 
 
N4 31.3 69.7 45.5 46.5               
 
N5 31.6 59.2 43.9 42.0 47.3             
 
N6 26.1 46.2 49.5 47.9 43.6 46.8           
 
N7 26.8 44.5 47.3 45.8 42.5 44.2 59.7         
 
N8 32.4 56.8 46.8 43.5 59.2 72.2 47.1 43.4       
 
N9 26.4 42.0 48.7 47.1 40.9 40.5 68.4 60.6 41.9     
 
N10 42.0 27.8 23.6 26.8 28.7 28.5 22.6 26.6 27.0 22.3   
 
Average 
influenza A 29.6 44.6 
 
Influenza B 26.3 33.6 30.4 30.9 33.6 34.5 31.7 31.5 34.0 32.1 23.7 
 
Average 
influenza B   31.6 
  
Table S5. Sequence comparison of A/bat/Peru/10 N11 NAL with bat N10 NALs and other influenza NAsa 
__________________________________________________________________________  
                             1       10        20        30                40        50  54                                                             
A/bat/Peru/10 N11            MSFQTS-TCLLIVSLICGILTVCLQVLLPFILIWTNTEPNYSCECPAPNISLSCPNGTSVTY 
GU10-060[H17N10]             MSINGT-TCLLTLSLILNIVMIGLQVLMPFVLLWTNSPP------PEIYNSTSCCNGTFLNE 
GU09-164[H17N10]             MSINGT-TCLLTLSLILNVIMIGLQILMPFILLWTNSPP------PEISNSTSCCNGTFLNE 
A/Tokyo/3/67[H2N2]           MNPNQKIITIGSVSLTIATVCFLMQIAILVTTVTLHFK--------QHDCDSPASNQVMPCE   
A/Brevig Mission/1/18[H1N1]  MNPNQKIITIGSICMVVGIISLILQIGNIISIWVSHSIQ------TGNQNHPETCNQSIITY 
B/Beijing/1/87               MLPSTI-QTLTLFLTSGGVLLSLYVSASLSYLLYSDIL-----------LKFSSKITAPTMT 
                            55   60           70        80        90       100       110                                                             
A/bat/Peru/10 N11            DSK--------NITENSFYSSTTNYLSPVIATPLVLGENLCSINGWVPTYRGEGTTGKI--- 
GU10-060[H17N10]             TNN--------NITN---ISQITNNFLKEEKFYWKARSQMCEVKGWVPTHRGFPWGPEL--- 
GU09-164[H17N10]             TNN--------NITN---ISQITNNFLKEEKFYWRAKSQMCEVKGWVPTHRGFPWGPEL--- 
A/Tokyo/3/67[H2N2]           PIIIERNITEIVYLN---NTTIEKEICPKVVEYRNWSKPQCQITGFAPFSKDNSIRLSA---    
A/Brevig Mission/1/18[H1N1]  ENNTWVNQTYVNISN---TNVVAGQDATS--VILTGNSSLCPISGWAIYSKDNGIRIGS--- 
B/Beijing/1/87               LDCANASNVQAVNRS---ATKEMTFLLPE-PEWTYP-RLSCQGSTFQKALLISPHRFGEARG 
                           111      120       130       140       150       160       170                                                             
A/bat/Peru/10 N11            PDEQMLTRQNFVSCSDKECRRFFVSMGYGTTTNFADLIVSEQ---MNVYSVKLGDPPTPDKL 
GU10-060[H17N10]             PGDLILSRRAYVSCDLTSCFKFFIAYGLSANQHLLNTSMEWE---ESLYKTPIGSANTLSTS 
GU09-164[H17N10]             PGDLILSRRAYVSCDLTSCFKFFIAYGLSANQHLLNTSMEWE---ESLYKTPIGSASTLSTS 
A/Tokyo/3/67[H2N2]           GGDIWVTREPYVSCDPVKCYQFALGQGTTLDNKHSNDTVHDRIPHRTLLMNELGVPFHLG-T   
A/Brevig Mission/1/18[H1N1]  KGDVFVIREPFISCSHLECRTFFLTQGALLNDKHSNGTVKDRSPYRTLMSCPVGEAPSPYNS 
B/Beijing/1/87               NSAPLIIRGPFIACGPKECKHFALTHYAAQPGGYYNGTREDRNKLRHLISVKLGKIPTVENS  
                            173    180       190       200       210       220       230                                                             
A/bat/Peru/10 N11            KFEAVGWSASSCHDGFQWTVLSVAG---DGFVSILYGGIITDTIHPTNGGPLRTQASSCICN                                    
GU10-060[H17N10]             EMILPGRSSSACFDGLKWTVLVSNGRDRNSFIMIKYGEEITDTFSASRGGPLRLPNSECICV 
GU09-164[H17N10]             EMILPGRSSSACFDGLKWTVLVANGRDRNSFIMIKYGEEVTDTFSASRGGPLRLPNSECICI 
A/Tokyo/3/67[H2N2]           RQVCIAWSSSSCHDGKAWLHVCITGDDKNATASFIYDGRLVDSIGSWSQNILRTQESECVCI   
A/Brevig Mission/1/18[H1N1]  RFESVAWSASACHDGMGWLTIGISGPDNGAVAVLKYNGIITDTIKSWRNNILRTQESECACV 
B/Beijing/1/87               IFHMAAWSGSACHDGREWTYIGVDGPDSNALIKIKYGEAYTDTYHSYANNILRTQESACNCI 
                           234   240       250       260       270       280        290 294                                                        
A/bat/Peru/10 N11            DGTCYTIIADGTTYTASSHRLYRLVNGTSAGWKALDTTGFNFEFPTCYYT-SGKVKCTGTNL 
GU10-060[H17N10]             EGSCFVLVSDGPNVNQSVHRIYELQNGTVQRWKQLNTTGINFEYSTCYTI-NNLIKCTGTNL 
GU09-164[H17N10]             EGSCFVIVSDGPNVNQSVHRIYELQNGTVQRWKQLNTTGINFEYSTCYTI-NNLIKCTGTNL 
A/Tokyo/3/67[H2N2]           NGTCTVVMTDGSASGRADTRILFIEEGKIVHISPLAGSAQHVEECSCYPR-YPGVRCICRDN   
A/Brevig Mission/1/18[H1N1]  NGSCFTIMTDGPSNGQASYKILKIEKGKVTKSIELNAPNYHYEECSCYPD-TGKVMCVCRDN 
B/Beijing/1/87               GGDCYLMITDGSASGISKCRFLKIREGRIIKEIFPTGRVEHTEECTCGFASNKTIECACRDN  
                           295  300       310       320       330       340       350   356                                                          
A/bat/Peru/10 N11            WNDAKRPFLEFDQ-SFTYTFKEPCLGFLGDTPRGID--TTNYC-DKTTTEGEGGIQGFMIEG  
GU10-060[H17N10]             WNDAKRPLLRFTK-DLNYQIVEPCNGAPTDFPRGGL--TTPSC-KMAQEKGEGGIQGFILDE 
GU09-164[H17N10]             WNDAKRPLLRFTK-ELNYQIVEPCNGAPTDFPRGGL--TTPSC-KMAQEKGEGGIQGFILDE 
A/Tokyo/3/67[H2N2]           WKGSNRPVVDINMEDYSIDSSYVCSGLVGDTPRNDDRSSNSNCRNPNNERGTQGVKGWAFDN   
A/Brevig Mission/1/18[H1N1]  WHGSNRPWVSFDQ-NLDYQIGYICSGVFGDNPRPNDGTG--SC-GPVSSNGANGIKGFSFRY 
B/Beijing/1/87               SYTAKRPFVKLNVETDTAEIRLMCTETYLDTPRPDDGSITGPC-ESNGDKGRGGIKGGFVHQ 
                           357    360       370       380       390        400       410                                                             
A/bat/Peru/10 N11            S-----NSWIGRIINPGSKKGFEIYKFLGTLFS-VQ-TVGNRNYQLLS-NSTIGRSGLYQP-  
GU10-060[H17N10]             K-----PAWTSKTKTELSQNGFVLEQIPDGIES-EG-TVS-LSYELFS-NKRTGRSGFFQP- 
GU09-164[H17N10]             K-----PAWTSKTKAESSQNGFVLEQIPNGIES-EG-TVS-LSYELFS-NKRTGRSGFFQP- 
A/Tokyo/3/67[H2N2]           G----NDLWMGRTISKDLRSGYETFKVIGGWSTPNSKSQI-NRQVIVDSDNRSGYSGIFSV-  
A/Brevig Mission/1/18[H1N1]  D----NGVWIGRTKSTSSRSGFEMIWDPNGWTETDSSFS--VRQDIVAITDWSGYSGSFVQH 
B/Beijing/1/87               RMASKIGRWYSRTMSKTERMGMELYVKYDGDPWTDSEALA-HSGVMVSMKEPGWYSFGFEI- 
                              413       420       430       440       450       460      469                                                       
A/bat/Peru/10 N11            ---AYESR-DCQELCFWIEIAATTKAG----LSSNDLITFCGTGGSMPDVNWG----------  
GU10-060[H17N10]             ---KGDLISECQRVCFWLEIEDQTVGL----GMIQELSTFCGINSPVQNINWDS--------- 
GU09-164[H17N10]             ---KGDLISGCQRICFWLEIEDQTVGL----GMIQELSTFCGINSPVQNINWDS--------- 
A/Tokyo/3/67[H2N2]           ---E-GK--SCINRCFYVELIRGRKQETRVWWTSNSIVVFCGTSGTYGTGSWPDGANINFMPI  
A/Brevig Mission/1/18[H1N1]  PELT-GL--DCMRPCFWVELIRGQPKE-NTIWTSGSSISFCGVNSDTVGWSWPDGAELPFSIDK  
B/Beijing/1/87               ---K-DK--KCDVPCIGIEMVHDGG---KKTWHSAATAIYCLMGSGQLLWDTVTGVDMAL--- 
______________________________________________________________ 
a Highly conserved sialic acid substrate-contacting residues (first-shell residues) in all flu A and B NAs are shown in 
purple, and green indicates largely conserved framework residues (second-shell residues) around active site in all the flu 
A and B NAs . Abbreviations: GU09-164, A/little yellow-shouldered bat/Guatemala/164/2009 (H17N10); GU10-060, 
A/little yellow-shouldered bat/Guatemala/060/2010 (H17N10). 
Table S6. Data collection and refinement statistics of A/bat/Peru/10 HA and A/bat/Peru/10 NAL 
Data set A/bat/Peru/10 HA 
crystal 1  
A/bat/Peru/10 HA 
crystal 2  
A/bat/Peru/10 NAL 
crystal form 1 
A/bat/Peru/10 NAL 
crystal form 2 
Space group I422 I422 I222 P61 
Unit cell (Å) a = b = 238.9, 
c = 160.8 
a = b = 239.1, 
c = 161.2 
a = 123.4, b = 164.4, 
c = 214.9 
a = b = 181.3, 
c = 136.6 
Resolution (Å) a 50.0-2.15 (2.23-2.15) 50.0-2.24 (2.32-2.24) 50.0-3.00 (3.11-3.00) 50.0-2.68 (2.73-2.68) 
X-ray source APS 23ID-D SSRL 11-1 APS 22ID SSRL 12-2 
Unique reflections 121,108 111,081 41,701 70,321 
Redundancy a 13.3 (6.4) 6.5 (6.3) 2.9 (2.5) 3.2 (3.3) 
Average I/σ(I) a 31.5 (1.9) 12.4 (2.4) 9.1 (1.4) 14.5 (1.0) 
Completeness a 97.1 (79.7) 99.8 (98.8) 94.5 (93.0) 98.4 (99.6) 
Rsymb 0.11 (0.76) 0.09 (0.59) 0.10 (0.70) 0.08 (0.69) 
Monomers in a.u. 3 3 4 4 
Vm (Å3/Da) 3.2 3.4 3.4 3.1 
Reflections used in 
refinement 
121,054 111,074 39,587 70,273 
Refined residues 1,476 1,482 1,452 1,417 
Refined waters 745 1,034 0 117 
Rcrystc 0.183 0.168 0.214 0.178 
Rfreed 0.220 0.200 0.260 0.220 
B-values (Å2) 
    Protein 
    Waters 
 
44.0 
46.7 
 
33.0 
37.3 
 
80.1 
- 
 
73.6 
58.5 
Wilson B-value (Å2) 
Ramachandran plot (%)e 
47.2 
97.9, 0.2 
34.4 
98.0, 0.5 
74.7 
94.5, 0.5 
79.8 
95.2, 0.3 
rmsd bond (Å) 0.008 0.007 0.014 0.009 
rmsd angle (deg.) 1.1 1.1 1.4 1.3 
PDB codes 4K3X 4MC5 4MC7 4K3Y 
a Parenthesis denote outer-shell statistics. 
b Rsym = ∑h∑i |Ii (h) - <I(h)>| /∑h∑i Ii (h), where < I(h)> is the average intensity of i symmetry-related 
observations of reflections with Bragg index h. 
c Rcryst = ∑hkl |Fo - Fc| / ∑hkl |Fo|, where Fo and Fc are the observed and calculated structure factors. 
d Rfree was calculated as for Rcryst, but on 5% of data excluded before refinement. 
e The values are percentage of residues in the favored and outliers regions analyzed by MolProbity. 
Table S7.  Comparison of Cα rmsd values (Å) of A/bat/Peru/10 HA (crystal 1) with other influenza A 
virus HAsa 
    Crystal 1             
(PDB code 
AA) 
Crystal 2          
(PDB code 
BB) 
Group Subtype Strain name PDB code HA1 HA2 HA1 HA2 
1 H1 A/South Carolina/1/1918 1RD8 1.4 1.2 1.4 1.1 
1 H1 A/Darwin/2001/2009 3M6S 1.3 0.7 1.4 0.8 
1 H1 A/swine/Indiana/P12439/00 4F3Z 1.5 0.9 1.5 0.9 
1 H2 A/Singapore/ 1/57 2WR7 1.4 0.8 1.4 0.8 
1 H5 A/Vietnam/1203/2004 2FK0 1.6 0.9 1.6 0.8 
1 H9 A/swine/Hong Kong/9/98 1JSD 1.9 1.0 1.9 1.0 
2 H3 A/Hong Kong/19/1968 2HMG 2.2 1.3 2.1 1.3 
2 H7 A/Netherland/219/2003 4DJ6 2.1 1.3 2.2 1.3 
2 H14 A/mallard/Astrakhan/263/1982 3EYJ 2.0 1.3 2.0 1.3 
 
aTo analyze differences in the overall structure, Cα r.m.s.d. values (Å) were calculated between the HA1 and 
HA2 subdomains of different HAs superimposed by sequential and structural alignment onto the equivalent 
domains of A/bat/Peru/10 HA. 
 
Table S8. Conservation of key residues in influenza A HA receptor-binding site a 
 
 Amino 
acid 
  
Residue number 
98 134 136 153 155 183 190 194 195 225 226 228 
Ala 0 1 11 0 4 0 367 0 0 4 2 2 
Cys 4 0 0 2 0 0 0 0 1 1 0 0 
Asp 1 0 3 0 0 1 6,497 0 0 4,514 0 3 
Glu 0 0 0 0 1 0 5,578 0 0 210 0 2 
Phe 13 0 0 0 0 0 0 3 1 0 0 0 
Gly 0 13,265 2 0 4 0 19 0 0 7,363 0 10,482 
His 2 0 0 0 878 12,789 1 0 5 1 5 0 
Ile 0 0 1 0 2,696 0 2 301 0 0 1,185 0 
Lys 0 0 0 0 1 0 2 0 0 5 2 0 
Leu 0 0 0 0 542 10 7 12,922 0 0 922 0 
Met 0 0 0 1 0 0 3 0 0 0 5 0 
Asn 0 3 0 0 0 464 309 0 1 968 0 0 
Pro 0 0 3 0 1 2 0 16 0 0 3 0 
Gln 0 0 0 0 3 1 5 0 0 0 10,029 0 
Arg 0 1 1 3 0 3 0 1 0 3 60 9 
Ser 0 1 8,104 1 4 0 1 0 1 6 0 2,646 
Thr 0 0 5,150 0 5,124 0 121 1 0 3 0 0 
Val 0 2 0 0 3,698 0 231 22 0 1 919 1 
Trp 0 2 0 13,268 0 0 0 0 0 0 0 1 
Tyr 13,256 0 0 0 264 0 2 1 13,261 0 0 0 
             
 H18 Phe c  Asn b  Aspb  Trp  Gln b  His  Glu  Tyr d Tyr  Gly  Hisc  Aspb  
 
a The incidence of an amino acid occurring at certain position is shown. A total of 13,282 (13,283 including 
A/bat/Peru/10 H18) full-length, non-redundant HA sequences from all influenza A viruses were available in the 
Influenza A Virus Resource at the NCBI in September 4, 2012. Red residues for H18 are consistent with the 
consensus sequences at that position in other influenza HAs.  
b Only in three bat influenza A virus HAs of A/bat/Peru/10 H18, GU09-164 H17 and GU10-060 H17. 
c Present in three bat HAs and a few other influenza A HAs. 
d Only in A/bat/Peru/10 H18 
Table S11. Conservation of key residues in the NA active site 
 
 Flu A NA (10,322)a Flu B NA (702)b 
Residues no. A/bat/Peru/10 
N11 
Consensusc  Consensusc 
118 R(10311) R(10311) R(702) 
119 Q(2)g E(10288) E(700) 
151 E(36) D(10031) D(696) 
152 Q(2)g R(10309) R(701) 
156 M(2)g R(10306) R(702) 
178 W(10,313) W(10313) W(702) 
179 S(10,317) S(10317) S(702) 
198 -h D(9514) D(698) 
222 P(3)d I(10244) I(694) 
224 R(10,298) R(10298) R(697) 
227 A(1)f E(10299) E(702) 
274 N(4)e H(9999) H(698) 
276 E(10,304) E(10304) E(702) 
277 F(1)f E(10308) E(702) 
292 T(4)e R(10306) R(701) 
294 L(3)d N(10295) N(701) 
371 K(3)g R(10314) R(701) 
406 R(3)d Y(10311) Y(701) 
425 E(10,318) E(10318) E(702) 
 
a The incidence of an amino acid occurring at certain position is shown in parentheses. A total of 10,321 full-
length, non-redundant NA sequences (10,322 to include A/bat/Peru/10 N11) from all influenza A viruses were 
available in the Influenza Virus Resource at the NCBI in September 4, 2012. Conserved residues are shown in 
red.  
b A total of 702 full-length, non-redundant NA sequences from all influenza B viruses were available in the 
Influenza Virus Resource at the NCBI in September 4, 2012. 
c Most common residue at position by simple majority across all NA sequences. 
d Only in three bat influenza A virus NALs of A/bat/Peru/10 N11, GU09-164 and GU10-060 N10s. 
e Present in three bat and one other influenza A virus NAs. 
f Only in A/bat/Peru/10 N11. 
g In A/bat/Peru/10 N11 and one or two other influenza A virus NAs. 
h Sequence deletion.  
Table S12. Seroprevalence of IgG in Guatemalan bats to H17 rHA by ELISA 
Species sampled in 2009 ELISA + Tested 
Artibeus jamaicensis  9 12 
Artibeus lituratus 2 7 
Carolia perspicillata 1 3 
Centurio senex 0 1 
Desmodus rotundus 9 41 
Glossophaga soricina 2 6 
Micronicterius nicrotis 0 3 
Phyllostomus discolor 2 2 
Pteronotus davyi  0 5 
Sturnira lilium 13 21 
Sturnida ludovici 0 1 
Vampyressa pusilla 0 2 
Species sampled in 2010 
  Artibeus jamaicensis 8 24 
Artibeus lituratus 3 5 
Artibeus phaeotis 1 1 
Artibeus toltecus 0 1 
Carollia perspicillata 2 8 
Desmodus rotundus 5 26 
Eptesicus fuscus 0 2 
Glossophaga soricina 7 13 
Macrophyllum macrophyllum 1 1 
Molossus sinaloae 0 2 
Myotis nigricans 0 2 
Platyrrhinus helleri 0 10 
Sturnira lilium 21 28 
Uroderma bilobatum 0 1 
Totals 86 228 
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SUPPORTING INFORMATION 
Supporting methods 
Cloning, expression and purification of A/bat/Peru/10 H18 HA protein used for crystal 2. 
The cDNA corresponding to the ectodomain of A/bat/Peru/10 HA (residues 15-513, equivalent 
to 11-329 of HA1 and 1-174 of HA2 in H3 numbering) was cloned into the baculovirus transfer 
vector, pAcGP67-A (BD Biosciences) in frame with an N-terminal gp67 signal peptide, a C-
terminal thrombin cleavage site, a foldon trimerization sequence [1], and a His6-tag to enable 
protein purification. Protein expressed from High Five™ cells was purified from the culture 
supernatant by metal affinity chromatography, subjected to thrombin cleavage and gel filtration 
chromatography. The purified trimeric H18 HA was subsequently buffer exchanged into 10 mM 
Tris-HCl, 50 mM NaCl, pH 8.0 and concentrated to 12.5 mg/ml for crystallization trials. The 
protein sample contained additional plasmid-encoded residues at both the N- (ADPG) and C-
termini (SGRLVPR). 
Cloning, expression and purification of A/bat/Peru/10 N11 NAL proteins used for crystal 
form 2 and for evaluation of neuraminidase activity. The ectodomain (residues 84-448, 
equivalent to 82-459 in N2 numbering) and ectodomain plus stalk region (residues 30-448, 37-
459 in N2 numbering) of A/bat/Peru/10 NAL protein were expressed in a baculovirus system for 
structural and functional analyses. The cDNAs corresponding to the NAL ectodomain and 
ectodomain plus stalk region of the A/bat/Peru/10 NA were inserted into a baculovirus transfer 
vector, pFastbacHT-A (Invitrogen) with an N-terminal gp67 signal peptide, a thrombin cleavage 
site, and a His6-tag [2]. The constructed plasmids were used to transform DH10bac competent 
bacterial cells by site-specific transposition (Tn-7 mediated) to form a recombinant Bacmid with 
beta-galactosidase blue-white receptor selection. The purified recombinant bacmids were used to 
 
transfect Sf9 insect cells for overexpression. The N11 NAL proteins were produced by infecting 
suspension cultures of Hi5 cells with recombinant baculovirus at an MOI of 5-10 and incubated 
at 28 ºC shaking at 110 RPM. After 72 hours, Hi5 cells were removed by centrifugation and 
supernatants containing secreted, soluble NALs were concentrated and buffer-exchanged into 20 
mM Tris pH 8.0, 300 mM NaCl, 2.5 mM CaCl2, and further purified by metal affinity 
chromatography using Ni-nitrilotriacetic acid (NTA) resin (Qiagen). For crystal structure 
determination, the N11 NAL ectodomain was digested with thrombin to remove the His6-tag. 
The cleaved NAL ectodomain was purified further by size exclusion chromatography on a 
Hiload 16/90 Superdex 200 column (GE healthcare) in 20 mM Tris pH 8.0, 100 mM NaCl, 10 
mM CaCl2 and 0.02% NaN3. For NA solution-based activity assay, the uncleaved ectodomain 
plus stalk region of the A/bat/Peru/10 NAL with His6-tag attached was concentrated after Ni-
NTA purification, in 100 mM imidazole-malate pH 6.15, 150 mM NaCl, 10 mM CaCl2, 0.02% 
NaN3. 
Crystal structure determination of A/bat/Peru/10 H18 HA in crystal form 2. Initial 
crystallization trials were set up using a TopazTM Free Interface Diffusion (FID) Crystallizer 
system (Fluidigm Corporation). Crystals were observed in conditions containing various 
molecular weights of PEG polymer. Following optimization, diffraction quality crystals for 
A/bat/Peru/10 HA were obtained at 20 °C using a modified method for microbath under oil [3], 
by mixing the protein with reservoir solution containing 0.05 M CaCl2, 30% (w/v) PEG MME 
550 and 0.1 M Bis-Tris buffer at pH 6.5. Crystals were flash-cooled at 100 K. Data were 
collected at the Stanford Synchrotron Radiation Lightsource (SSRL) beamline 11-1 at 100 K and 
processed with the DENZO-SCALEPACK suite [4].  
 
The structure of A/bat/Peru/10 HA was determined by molecular replacement with 
Phaser [5] using the H2 HA structure from A/Singapore/1/1957 (PDB code 2WR7, 53% identity) 
as the MR search model. The MR solution identified a trimer of three HA monomers related by a 
non-crystallographic 3-fold with an estimated solvent content of 63.7% based on a Matthews’ 
coefficient (Vm) of 3.4 Å3/Da. The model was then “mutated” to the correct sequence and rebuilt 
by Phenix Autobuild [6] and Coot [7], and the structure was refined with Refmac5 [8] and 
Phenix Refine [9]. The final model was assessed using MolProbity [10]. Statistics on data 
processing and refinement are presented in Table S6. 
Crystal structure determination of A/bat/Peru/10 N11 NAL in crystal form 2. 
Crystallization experiments were set up using the sitting drop vapor diffusion method. The 
A/bat/Peru/10 NAL crystal in form 2 was obtained by mixing the NAL ectodomain monomer at 
10 mg/ml in 20 mM Tris pH 8.0, 100 mM NaCl, 10 mM CaCl2 and 0.02 % NaN3 with 0.2 M 
K2SO4, and 18% (w/v) polyethylene glycol 3350 at 22 °C. The A/bat/Peru/10 NAL crystals were 
cryoprotected in mother liquor with addition of 6.4% (w/v) PEG 3350 before being flash-cooled 
at 100 K. Diffraction data were collected at beamline 12-2 at SSRL. Data for all crystals were 
integrated and scaled with HKL2000 [4]. 
The A/bat/Peru/10 NAL structure was determined by molecular replacement using the 
program Phaser [5] with the A/little yellow-shouldered bat/Guatemala/164/2009 (H17N10) N10 
NAL structure (PDB code 4GDI) as the MR starting model. Initial rigid body refinement was 
performed in Refmac5 [8] and simulated annealing and restrained refinement (including TLS 
refinement) were carried out in Phenix [11]. Between rounds of refinements, model building was 
carried out with the program Coot [7]. Final data processing and refinement statistics are 
represented in Table S6. The quality of the structure was analyzed using the JCSG validation 
 
suite (www.jcsg.org). All figures were generated with Bobscript [12] except for Fig. 2C and D, 
which was generated with PyMol (www.pymol.org). 
HA enzyme-linked immunosorbent assay (ELISA) based plate assay for glycan binding. 
Protocols for ELISA-based glycan binding assay were as previously described [13]. Briefly, 50 
µl of 1.6 mM biotinylated glycans (NeuAcα2-6Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAc (6’-
SLNLN) and NeuAcα2-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAc (3’-SLNLN), obtained from the 
Consortium for Functional Glycomics) were loaded onto a streptavidin-coated high binding 
capacity 384-well plate (Pierce) overnight at 4 ºC. The plate was washed with PBS buffer and 
incubated with HA-antibody complexes comprised of His-tagged HA protein, and primary 
antibody (mouse anti-Penta-His antibody, Qiagen) and secondary antibody (horseradish 
peroxidase (HRP)-conjugated goat anti-mouse IgG, Pierce) at a weight ratio of 4:2:1. After 
incubation for 2 hours at room temperature (~22 ºC) and extensive wash with PBST and PBS, 
HRP activity was measured using Amplex Red hydrogen peroxide/peroxidase assay kit 
(Invitrogen). 
HA glycan microarray receptor binding assay. Protocols for microarray HA analysis were as 
previously described [14,15]. Briefly, HA-antibody complexes were prepared by mixing 15 µg 
of recombinant HA, mouse anti-His Alexa Fluor 488 (Qiagen) and goat anti-mouse IgG Alexa 
Fluor 488 (Invitrogen) in a molar ratio of 4:2:1, respectively, in 20 mM Tris pH 8.0, 100 mM 
NaCl, and 0.02% NaN3 buffer. These prepared complexes were incubated on ice for 15 min, and 
100 µL of the complex mixture was then added directly to the surface of the array and allowed to 
incubate for 1 hour at room temperature (~ 22 ºC) in a humidified chamber, protected from the 
light. After the initial incubation, HA-antibody solution was removed by pipetting the solution 
and washing 3 times with 100 µL 1x PBS + 0.05% Tween, pH 7.4, and, subsequently, by dipping 
 
3 times in 1x PBS and then 3 times in distilled H2O. Washed slides were dried by centrifugation 
and scanned on a ProScanArray Express HT (PerkinElmer) confocal slide scanner for 
AlexaFluor488 setting. Image data were stored as a TIFF image and signal data was collected 
using Imagene (BioDiscovery) imaging software. The signal data were processed to determine 
averaged (mean signal minus mean background) values of 4 replicate spots on the array for each 
unique printed glycan.  Two different arrays were analyzed.  One is a custom sialoside array 
comprising 58 sialosides described previously [14], and the other is glycan array version 5.1 
provided by the CFG containing 610 glycans of diverse structure (Table S9).  Results from the 
v5.1 glycan microarray are deposited to the CFG database (http://www.functionalglycomics.org/). 
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